Federal authorities have now moved from warnings to criminal charges against the people they say run CANARX, a Canadian company that ships prescription drugs to American patients. According to court records filed Tuesday, John Thomas Howard, the company's treasurer and a director, was arrested Sunday on smuggling and conspiracy charges. His brother, Bob Howard, the president and a director, is wanted in the same federal investigation, according to an affidavit from FDA special agent Dustin Dobbs. No plea has been filed, and the Howards deny all the charges.

The affidavit's central claim is that the FDA found probable cause to believe CANARX illegally imported or caused the illegal importation of prescription drugs into the United States. That is an allegation, not a verdict, and it should be tested in court. But the record behind it is not new. The FDA sent CANARX a warning letter in 2019 about substituting unapproved drugs for FDA-approved ones, and the agency seized shipments in 2023 that it said were potentially misbranded and counterfeit. The company's general counsel, Joseph Morris, said in 2019 that CANARX agreed to stop importing drugs that must be administered by a doctor, while arguing it was not misleading patients.

The broader issue is the business model. CNBC's investigation found that these alternative funding programs are spreading through private and public employers by offering high-cost specialty drugs at lower prices, and that some employers require staff to use them. An FDA spokesperson told CNBC that, in most circumstances, a person cannot import prescription drugs from other countries as substitutes for FDA-approved drugs. A pending civil suit by Gilead Sciences over its HIV medication Biktarvy makes the stakes concrete for patients whose treatment depends on verified supply.

Small businesses and employers that offer these programs as a cost-saving benefit should treat this case as a warning. A lower sticker price means little if the product's origin, storage and labeling cannot be verified. Employers should ask hard questions about any vendor that sources medication overseas before enrolling staff, and should not assume that a company's claim to be the safest program in the industry is the same as legal compliance.

Regulators should move faster to close the gap between what these companies advertise and what the law permits, and prosecutors should follow the case to a conclusion. The Howards are entitled to a defense, and the charges may not hold. Still, the questions raised here about patient safety and supply-chain integrity are too serious to wait for a courtroom outcome.